A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Approval of Spravato, granted following FDA priority review, was based on the results of a randomized, double-blind, ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.